Loading
ROR1 is a fetal pseudo-kinase receptor re-expressed on over 90% of chronic lymphocytic leukaemias, 30 to 50% of diffuse large B-cell lymphomas and 40 to 60% of triple-negative breast cancers, and largely absent from healthy adult tissue. Zilovertamab vedotin uses it as an ADC address, in phase 3 in large B-cell lymphoma; whether expression level predicts benefit is unproven. This dossier gathers the 1 product (0 approved), 8 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Wnt5a pseudo-kinase receptor; drives survival signalling in CLL and MCL.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Chronic lymphocytic leukaemia | >90% | Surface expression | Wikipedia | |
| Triple-negative breast cancer | 40-60% | IHC, any expression | Wikipedia | |
| Diffuse large B-cell lymphoma | 30-50% | IHC, any expression | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Phase 3 |
|---|---|
| ADC 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Recruiting | A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010) | - | ||
waveLINE-003 NCT05139017 | 2/3 | Recruiting | R/R DLBCL after ≥1 line: zilovertamab vedotin + R-GemOx vs R-GemOx | - | |
| 2 | Recruiting | A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL) | - | ||
| 2 | Active | A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (waveLINE-006) | - | ||
| 2 | Active | A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP in Participants With DLBCL (waveLINE) | - | ||
| 1/2 | Recruiting | A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A | - | ||
| 1/2 | Recruiting | Phase 1/2, Biomarker-guided, Open-label Study of Allogeneic Dual-target CAR-NK Cells Directed Against HER2/ERBB2, MUC1, and/or ROR1 in Patients With Advanced or Metastatic Breast Cancer (Including HER2-positive and Triple-negative Disease). | - | - | |
| 1/2 | Recruiting | LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"ROR1" OR ABSTRACT:"ROR1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ROR1, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/ror1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ror1.json. Licence CC BY-NC 4.0.